Financial Snapshot For March 2004: Looking Good
“It’s been a rocky first quarter for the biotech stocks � and for the markets in general. Yet, despite investors’ nervousness � about issues as diverse as the terrorist train bombing in Madrid and the departure of Mark McClellan from the FDA � the biotech sector managed to hold its own, and even out-performed the Nasdaq Composite Index.”